In moderate-
randomized placebo-controlled trial of de novo patients treated with donepezil in moderate-to-severe AD (MMSE range 5 to 17) found an overall functional stabilization with donepezil compared with a significant decline in the placebo group, 8 with a particularly beneficial effect on the initiation component of completing ADL as measured by the DAD. 9 Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate-receptor antagonist approved in the United States, Canada, and Europe for the treatment of moderate-to-severe AD. 10, 11 Efficacy and safety of memantine in moderate-to-severe AD have been established in several clinical trials (additional information also available at www.forestclinicaltrials.com). [12] [13] [14] A recent placebo-controlled trial evaluated memantine in patients with moderate-to-severe AD receiving stable donepezil treatment. 10 The 19-item ADCS-ADL inventory (ADCS-ADL 19 ) was a coprimary outcome measure. In this report, ADCS-ADL 19 data are further analyzed to investigate the impact of memantine on individual and grouped ADL items.
METHODS

Patients and Study Design
The data reported are secondary post hoc analyses of a prospective, randomized, double-blind, placebocontrolled, 24- week study of memantine in combination with donepezil in community-dwelling patients with moderate-to-severe AD conducted at 37 US sites. For a more detailed description of the study design, please refer to Tariot et al. 10 Briefly, 404 patients were diagnosed with probable AD, according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer Disease and Related Disorders Association criteria. Study inclusion criteria were MMSE score of 5 to 14, age at least 50 years old, a recent magnetic resonance imaging or computed tomography scan consistent with AD diagnosis, ongoing donepezil therapy for more than 6 months before entrance into the trial and at a stable dose (5 to 10 mg/d) for at least 3 months. Caregivers were knowledgeable about the patients, accompanied them to research visits, and oversaw the administration of the investigational drug during the trial. Patients were medically stable and ambulatory. Stable doses of concomitant medications including psychotropics were permitted. Written informed consent was obtained from caregiver and patient (if possible), or a legally acceptable representative, before initiating study-specific procedures. The study was reviewed and approved by each site's institutional review board.
Patients were randomized to double-blind treatment with placebo or memantine after a 1-week to 2-week single-blind placebo lead-in. Memantine was titrated in 5-mg weekly increments beginning at 5 mg/d to a maintenance dose of 20 mg/d at week 4. Medication was administered in divided doses twice daily. All patients continued stable doses of donepezil throughout the study.
Outcome Measures
The primary measure for these analyses was the ADCS-ADL 19 (1 of 2 prospectively defined primary outcome measures). Designed specifically for moderateto-severe AD, the ADCS-ADL 19 was developed from a subset of 45 ADL items that were originally evaluated in a sample of 242 patients with probable AD. 6 The 19-item version has been shown to be a valid and reliable measure of functional decline in this patient population. 15 The ADCS-ADL 19 is administered as an interview with the caregiver and is focused on the performance of each ADL during the prior 4 weeks. 6 Possible scores range from 0 to 54. For each ADL item, 0 reflects inability to perform an activity or the need for extensive help, and the highest score represents complete independence. The ADCS-ADL 19 was administered at baseline and at weeks 4, 8, 12, 18, and 24.
Cognitive, behavioral, and global outcome measures were obtained. 10 The coprimary outcome measure was the Severe Impairment Battery. 16, 17 The Neuropsychiatric Inventory 18, 19 and the Behavioral Rating Scale for Geriatric Patients 20 assessed behavioral symptomatology, and the Clinician's Interview-Based Impression of Change With Caregiver Input (ADCS version) 21 assessed the patient globally.
Statistical Analyses
All randomized patients receiving at least 1 dose of medication were included in safety, demographics, and baseline analyses (n = 403). Efficacy analyses were derived from the intent-to-treat population (n = 395), which included randomized patients receiving more than 1 dose of medication and completing at least 1 postbaseline primary assessment.
Observed case (OC) and mixed model repeated measures (MMRM) approaches are reported. An advantage of MMRM analyses over both OC and the traditional last observation carried forward approach is that they use all available data to impute performance at end point. The MMRM analyses used treatment group, week, center, and treatment group-by-week interaction as factors and baseline scores as covariates. An unstructured covariance matrix was used for the repeated measures and corrected least squares means are reported.
For responder analyses, a generalized estimating equations (GEE) approach, an adaptation of generalized linear modeling, was used. 22 The GEE method takes into account the correlation between repeated observations on individual subjects that occurs when subjects are evaluated with the same outcome measures over time. For these analyses, an unstructured covariance matrix was used to model the correlation over time. The difference in the proportion of responders between groups, termed absolute risk reduction (ARR), was analyzed for significance using a Wald w 2 test at the a = 0.05 level of significance with no adjustments for multiple comparisons. 23 Finally, an additional measure of treatment effect, the number needed to treat (NNT), was calculated. It is the inverse of the ARR and is considered useful in rendering research trial data meaningful for clinical decision making. 15 In this case, the NNT is the number of patients who need to be treated for one additional patient to respond according to a specified criterion. 24 Change in the total score of the ADCS-ADL 19 was first analyzed using MMRM and OC approaches. Next, the distribution of change scores for each treatment group was examined based on 5-point intervals. A Cochran-Mantel-Haenszel test controlling for study center was performed on the treatment distributions. Finally, a series of responder analyses was performed using different thresholds of response and tested with GEEs.
Four subscales were derived from a factor analysis on the covariance matrix using a varimax rotation, and factors retained had eigenvalues of at least 1 ( Table 1) . Subscales took the sum of each item that loaded at 0.30 or greater; items that loaded on multiple factors were included on the factor with the highest loading. Change was analyzed using MMRM and OC approaches, and a responder analysis (defined as no change or improvement) was performed with GEE. Because of the hypothesis-generating aspect of these analyses, all testing was conducted at Pr0.05, with no adjustment for multiple comparisons using SAS version 9.1.3. Table 2 shows the demographics and clinical characteristics of the study population of 404 patients (placebo: 201; memantine: 203). 10 More patients (85%) receiving memantine completed the study than those receiving placebo (74.6%). Patients receiving memantine demonstrated significantly better total scores on the ADCS-ADL 19 at week 24 than patients receiving placebo ( Fig. 1 ) (least square mean difference between placebo and memantine [95% confidence intervals]: MMRM, À 1.2 [ À 1.99, À 0.36], P = 0.005; OC, À 1.6 [ À 2.9, À 0.3], P = 0.02). 10 When examining change on the ADCS-ADL 19 , patients receiving memantine showed more improvement (Z0 points), whereas patients receiving placebo showed greater worsening (particularly with loss of Z6 points) ( Fig. 2 ). However, a statistically significant difference was not observed between these 2 treatment distributions (P = 0.141). For stabilization or improvement (Z0 points on the ADCS-ADL 19 total score) in the OC analysis, the NNT was 10.
RESULTS
When treatment response was defined as no change or improvement relative to baseline, memantine yielded higher rates of improvement than placebo for most ADCS-ADL 19 increments ( Table 3 ). The ARR between memantine and placebo ranged from 4.4% to 10.4% in favor of memantine and was significant for each increment, except for Z4 points (OC) and for at least 8 points (OC/MMRM). The NNT ranged from 10 to 23 (OC). Within the placebo group, the largest declines in change scores were found on ADL skills of toileting, grooming, and dressing, as well as being left alone (Table 4 ). Overall in the placebo group, there were 5 items whose mean item scores did not change and 14 items that evidenced decline at 24 weeks. No ADCS-ADL 19 items improved. Within the memantine group, there were 3 individual items whose mean scores improved, 8 items that did not change, and 8 items that declined. Results of the MMRM analysis revealed a significant treatment effect for memantine on 5 items: toileting (P = 0.030), grooming (P = 0.019), watching television (P = 0.009), conversing (P = 0.048), and being left alone (P = 0.034). On the basis of OC analysis, treatment with memantine demonstrated significant benefit compared with placebo on 3 items: grooming (P = 0.002), watching television (P = 0.008), and finding belongings (P = 0.011).
When examining change on the ADCS-ADL 19 subscales, the higher-level subscale functions showed significant benefit for memantine compared with placebo at week 24 (MMRM: P = 0.015; OC: P = 0.011). Similarly, the subscale connectedness/autonomy significantly favored memantine (MMRM: P = 0.015; OC: P = 0.033) ( Table 4 ). A similar pattern emerged with responder analyses whereby both subscales reached statistical significance: higher-level functions (61.6% vs. 48.0%, GEE: P = 0.04; OC: P = 0.008) and connectedness/autonomy (57.0% vs. 46.7%, GEE: P = 0.01; OC: P = 0.053).
DISCUSSION
The current study provides important data on the patterns of functional decline that occur in patients with moderate-to-severe AD who were followed over a 6-month period. These results indicate that with a history of 2.5 years (on average) of donepezil treatment, patients will either decline or remain unchanged on every individual ADL item over 6 months, while no individual skill seems to improve. The response pattern with memantine is different. There are a greater number of individual items that, on average, remain unchanged, whereas in contrast to placebo, there are individual items that improve.
On the basis of the ADL total score, memantine showed relatively consistent benefit over placebo. For responder analyses, the benefit of memantine was maintained throughout using the GEE approach (from no change/improvement using responder definition up to 4 points or more), with similar response using an OC approach. On the whole, these findings suggest that memantine has the potential to offer benefit across a range of functional abilities in moderate-to-severe AD.
Subscales help clarify the pattern of ADL changes. The ADL factor includes the usual items of eating, toileting, and grooming, activities previously recognized and used as outcome measures. 25 The simple motor skills/ praxis factor allows for evaluation of the breakdown of motor skills and sequences that impact on caregiving. These items require a caregiver to take over functions no longer performed independently, adding to time spent assisting with ADL. The connectedness/autonomy component touches on the important dimension of retaining aspects of functional autonomy in moderate-to-severe AD. The ability to be left alone, to travel outside the home, and to engage in some activities inside the home all carry important implications for the quality of life for both patient and caregiver. Similarly, higher-level functions such as conversing, obtaining a beverage, and finding belongings touch on spontaneous actions in daily activities that reflect one's engagement and forming of intention.
The present analysis shows that the memantine treatment was associated with significant benefit on the connectedness/autonomy and higher-level functioning factors or item subgroups. The impact on these domains suggests that treatment with memantine relates to improving spontaneity and engagement in ADL, as well as preserving and improving residual functional autonomy. These results help to translate memantine's benefits on ADL into a more qualitative understanding of the clinical meaningfulness of treatment.
These analyses have limitations in that they are post hoc and the trial from which data were derived did not include an item or factor analysis a priori. There was no effort to control for repeated testing, which was necessary owing to the hypothesis-generating nature of these analyses. These results have potential for bias, having been taken from one of three 6-month trials of memantine conducted in moderate-to-severe AD. Future prospective studies are recommended to confirm these findings. Nonetheless, these data support the potential importance of ADL as an outcome in moderate-to-severe AD and underscore the potential role of ADL as a clinically meaningful primary outcome measure.
In conclusion, these data suggest that memantine seems to be associated with an overall benefit in function in patients treated with stable donepezil. 
